# Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.

> **NCT04293172** · PHASE3 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Brilinta
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04293172
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-30
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study halted prematurely, prior to enrolment of first patient.
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04293172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04293172, "Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04293172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*